MX2021010483A - Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf). - Google Patents

Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).

Info

Publication number
MX2021010483A
MX2021010483A MX2021010483A MX2021010483A MX2021010483A MX 2021010483 A MX2021010483 A MX 2021010483A MX 2021010483 A MX2021010483 A MX 2021010483A MX 2021010483 A MX2021010483 A MX 2021010483A MX 2021010483 A MX2021010483 A MX 2021010483A
Authority
MX
Mexico
Prior art keywords
istaroxime
heart failure
disclosed
metabolites
ahf
Prior art date
Application number
MX2021010483A
Other languages
English (en)
Inventor
Giuseppe Bianchi
Patrizia Ferrari
Mara Ferrandi
Paolo Barrassi
Original Assignee
Windtree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windtree Therapeutics Inc filed Critical Windtree Therapeutics Inc
Publication of MX2021010483A publication Critical patent/MX2021010483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se desvelan composiciones para infusión intravenosa de istaroxima, o un metabolito de istaroxima, en pacientes humanos que padecen insuficiencia cardíaca. De forma análoga, se desvelan métodos para la infusión prolongada de istaroxima o sus metabolitos en individuos con insuficiencia cardíaca. En particular, algunos métodos descritos en este documento incluyen la infusión de istaroxima, o un metabolito de la misma, durante un período de tiempo que es superior a seis horas para mejorar la relajación cardíaca sin desencadenar eventos arritmogénicos en un individuo que padece insuficiencia cardíaca. Otros métodos incluyen la administración de istaroxima hasta que se alcancen ciertos umbrales de concentración en plasma de metabolitos de istaroxima. También se describen metabolitos de istaroxima con activación selectiva de SERCA2a.
MX2021010483A 2019-03-05 2019-11-12 Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf). MX2021010483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814149P 2019-03-05 2019-03-05
PCT/US2019/060961 WO2020180356A1 (en) 2019-03-05 2019-11-12 Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)

Publications (1)

Publication Number Publication Date
MX2021010483A true MX2021010483A (es) 2021-10-01

Family

ID=69160228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010483A MX2021010483A (es) 2019-03-05 2019-11-12 Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).

Country Status (12)

Country Link
US (3) US11197869B2 (es)
EP (1) EP3934654A1 (es)
JP (1) JP7560134B2 (es)
KR (1) KR20210136048A (es)
CN (1) CN112118846B (es)
AU (1) AU2019432709A1 (es)
BR (1) BR112021017009A2 (es)
CA (1) CA3130261A1 (es)
IL (1) IL285921A (es)
MX (1) MX2021010483A (es)
SG (1) SG11202108488SA (es)
WO (1) WO2020180356A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805243B1 (en) * 2019-10-09 2023-11-15 Windtree Therapeutics, Inc. Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure
TW202245792A (zh) * 2021-01-22 2022-12-01 美商風樹療法公司 靜脈注射伊司他星用於治療急性心臟衰竭
WO2023205183A1 (en) 2022-04-20 2023-10-26 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
DE19633349A1 (de) 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
JP2000516641A (ja) 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
IT1317031B1 (it) 2000-05-17 2003-05-26 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione di (e,z)3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
EP1698329A4 (en) 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
JP4959570B2 (ja) 2004-10-18 2012-06-27 日東電工株式会社 細胞内ペプチド送達
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20100087374A1 (en) * 2008-10-03 2010-04-08 Shama Ahmad Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein
WO2010040110A1 (en) * 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
CA2889584C (en) * 2012-10-26 2018-08-14 The Medicines Company Methods for controlling blood pressure and reducing dyspnea in heart failure
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CN103315968B (zh) * 2013-06-26 2015-04-01 中国生命药物治疗有限公司 一种注射用粉针剂及其制备方法
TW202245792A (zh) * 2021-01-22 2022-12-01 美商風樹療法公司 靜脈注射伊司他星用於治療急性心臟衰竭

Also Published As

Publication number Publication date
US20230293548A1 (en) 2023-09-21
WO2020180356A1 (en) 2020-09-10
US20210252017A1 (en) 2021-08-19
US11583540B2 (en) 2023-02-21
AU2019432709A1 (en) 2021-09-02
KR20210136048A (ko) 2021-11-16
SG11202108488SA (en) 2021-09-29
US11197869B2 (en) 2021-12-14
CN112118846A (zh) 2020-12-22
IL285921A (en) 2021-10-31
JP2022523821A (ja) 2022-04-26
WO2020180356A9 (en) 2020-11-12
BR112021017009A2 (pt) 2021-11-09
JP7560134B2 (ja) 2024-10-02
CA3130261A1 (en) 2020-09-10
EP3934654A1 (en) 2022-01-12
US20220054502A1 (en) 2022-02-24
CN112118846B (zh) 2024-04-16

Similar Documents

Publication Publication Date Title
MX2021010483A (es) Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
Dougherty et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem
EP3824945A3 (en) Electrical stimulation system
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
Del Seppia et al. Evidence in hypertensive rats of hypotensive effect after mandibular extension
Yagishita et al. Idiopathic ventricular fibrillation associated with early repolarization which was unmasked by a sodium channel blocker after catheter ablation of atrial fibrillation
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
Logarzo et al. P3875 Para-hisian pacemaker implantation technique guided by Synchromax method
Amadori et al. Antiarrhythmic drug therapy in the treatment of acute and chronic atrial flutter
Abbas et al. Use of pacemaker in GBS dysautonomia
Büchner et al. Investigation of stimulation rates between 500 and 5000 pps with the Clarion 1.2, Nucleus CI24 and Clarion CII devices
EP4241838A3 (en) Use of ribose for treatment of subjects having congestive heart failure
Stoicescu The Risk of sudden decrease of severe arterial hypertension
Sahpaz et al. An unusual clinical case of bradycardia and confusion: Mad honey intoxication by grayanotoxin
Reichlin et al. P3873 Introduction of leadless transcatheter intracardiac pacing: assessing the initial learning curve
Young et al. Comparison of the relationship between factor IX activity and bleeding risk during prophylaxis with nonacog beta pegol (N9-GP)
Gartrell et al. Typical hormone deprivation side effects compared to SM-88 therapy for rising PSA
Charle et al. Reviewing the causes of electrocardiographic pauses
Behera et al. Temporary cardiac pacing induced electrocardiographic changes simulating myocardial infarction
Ozcete et al. Cardiac arrest due to a lethal dose of propafenone and first case to survive following treatment with intravenous fat emulsion
Louka et al. IVABRADINE’S POTENT EFFECT ON THE AV NODE: A CASE OF 2ND DEGREE HEART BLOCK
Limb Offer regular HIV tests to high risk groups to reduce late diagnoses, says public health agency
Barold et al. Paroxysmal atrioventricular block precipitated by an atrial premature beat. What is the mechanism?
Adorisio et al. P5275 Heart rate reduction strategy with ivabradine is effective in reducing acute heart failure in duchenne dilated cardiomyopathy
Morera Calcium gluconate